Concurrent Use of Oral NSAIDs and Topical Diclofenac

Critical Safety Concerns with Combination Therapy

• The National Comprehensive Cancer Network recommends that the risk of gastrointestinal bleeding, ulceration, and perforation increases substantially when multiple NSAIDs are combined, with no meaningful increase in therapeutic efficacy 1, 2
• The American Heart Association suggests that all NSAIDs, including diclofenac, carry a risk of increased cardiovascular thrombotic events, myocardial infarction, and stroke, with diclofenac showing an elevated cardiovascular risk with an odds ratio of 1.63 for vascular events 3

Clinical Alternatives to Combination Therapy

• The National Comprehensive Cancer Network recommends using topical diclofenac alone for localized musculoskeletal pain, which provides therapeutic benefit with significantly lower systemic absorption than oral NSAIDs 1, 2
• The National Comprehensive Cancer Network suggests substituting acetaminophen as the systemic analgesic instead of oral NSAIDs, and adding adjuvant analgesics such as gabapentin or pregabalin for neuropathic components rather than increasing NSAID exposure 1, 2, 4

Risk Mitigation if Oral NSAIDs are Essential

• The National Comprehensive Cancer Network recommends using the lowest effective dose for the shortest duration, and adding proton pump inhibitor prophylaxis for gastrointestinal protection 1, 2, 5

High-Risk Populations Requiring Absolute Avoidance

• The National Comprehensive Cancer Network and Praxis Medical Insights recommend that the combination of oral and topical NSAIDs should never be used in patients with active peptic ulcer disease, history of NSAID-related GI bleeding, those on therapeutic anticoagulation, patients with severe renal impairment, individuals with decompensated cirrhosis, patients with recent MI or undergoing CABG surgery, and elderly patients with multiple cardiovascular risk factors 1, 2, 3, 4